{"nctId":"NCT00689338","briefTitle":"Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study","startDateStruct":{"date":"2008-07"},"conditions":["Invasive Candidiasis"],"count":216,"armGroups":[{"label":"Treatment Group","type":"EXPERIMENTAL","interventionNames":["Drug: Anidulafungin","Drug: Fluconazole","Drug: Voriconazole"]}],"interventions":[{"name":"Anidulafungin","otherNames":[]},{"name":"Fluconazole","otherNames":[]},{"name":"Voriconazole","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nICU patients with a diagnosis of documented candidemia or invasive candidiasis and belonging to one or more of the following specific populations:\n\n* Post-abdominal surgery.\n* Elderly \\> 65 years old.\n* Renal insufficiency / failure / hemodialysis.\n* Solid tumor.\n* Solid-organ (liver, kidney, lung, heart) transplant recipients.\n* Hepatic insufficiency.\n* Neutropenic including hematology oncology patients.\n\nExclusion Criteria:\n\nPatients with poor venous access that would preclude IV drug delivery or multiple blood draws.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With Global Treatment Response Success at End of Treatment","description":"Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"69.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Global Response Success at End of Intravenous Treatment (EOIVT)","description":"Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Global Response Success at 2 Weeks After End of Treatment","description":"Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Global Response Success 6 Weeks After End of Treatment","description":"Global response based on combination of clinical and microbiological outcomes; success defined as clinical response of cure (resolution of signs and symptoms of Candida infection) or improvement (significant, but incomplete resolution of signs and symptoms of Candida infection) in conjunction with microbiological eradication (follow-up culture negative for Candida species) or presumed eradication (follow-up culture not available and clinical response of success).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to First Negative Blood Culture","description":"Negative blood culture defined as first negative culture that was not followed by a positive culture within the next 3 days (or 4 days if negative culture was observed on or after Day 10) from start of study medication until end of intravenous treatment (EOIVT). Time to first negative culture includes the first day of study medication.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Day 90 Survival","description":"Percentage of participants known or assumed to be alive on Day 90.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"54.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Successful Intensive Care Unit (ICU) Discharge","description":"Time from start of study medication to successful ICU discharge (by end of treatment \\[EOT\\]), defined as being alive on the day after the EOT visit, not being in the ICU on the day after the EOT visit, and being classed as a global treatment success at EOT.","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":107,"n":216},"commonTop":["Diarrhoea","Anaemia","Hypertension","Hypotension","Nausea"]}}}